Raziel Therapeutics

Portfolio companies

Founded in 2012, Raziel Therapeutics is a clinical-stage pharmaceutical company developing a proprietary drug for the treatment of local fat reduction. The company is targeting obesity and related indications. The lead program, RZL-012, is a compound that kills fat cells and is administered subcutaneously to combat local fat build-up.

Management team consists of professionals with many years of experience in the high-tech and biopharmaceutical industry, including Chairman Philippe Schaison, a reputed veteran of the aesthetics industry.